No Data
No Data
Wedbush Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $25
LifeSci Capital Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $24
Buy Rating on Perspective Therapeutics Backed by Promising VMT-alpha-NET Clinical Results
Wedbush Initiates Perspective Therapeutics(CATX.US) With Buy Rating, Announces Target Price $25
Perspective Therapeutics Initiated With an Outperform at Wedbush
Perspective Therapeutics to Present at the 37th Annual Congress of the European Association of Nuclear Medicine